Granulocytopenia adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 5,645 adverse event reports that record the MedDRA preferred term Granulocytopenia. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 159 reports in the 12 months to June 2026 and 143 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,351 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 159 (under 0.1%) record this term. Reports for patients aged 18 to 44 were 29.9% of the reports that record this term and 12.3% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 93 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Granulocytopenia name as a suspect product, in order of name
Drug	Class	Reports with this term
0 9% Sodium Chloride Injection		26
5% Glucose Injection		18
Abilify	Atypical antipsychotic	25
Acetylsalicylic Acid		11
Adriamycin		10
Aripiprazole	Atypical antipsychotic	12
Azacitidine	Nucleoside metabolic inhibitor	32
Bevacizumab	Vascular endothelial growth factor inhibitor	40
Capecitabine	Nucleoside metabolic inhibitor	31
Carboplatin	Platinum-based drug	104
Cefuroxime axetil	Cephalosporin antibacterial	14
Chemotherapeutics		19
Cisplatin	Platinum-based drug	74
Clozapine	Atypical antipsychotic	3,171
Clozapine Teva		246
Clozaril	Atypical antipsychotic	48
Cyclophosphamide	Alkylating drug	198
Cyclosporine	Calcineurin inhibitor immunosuppressant	13
Cytarabine	Nucleoside metabolic inhibitor	79
Depakine Chrono		12
Depakote	Anti-epileptic agent	41
Dexamethasone	Corticosteroid	41
Dextrose		17
Docetaxel	Microtubule inhibitor	75
Doxorubicin	Anthracycline topoisomerase inhibitor	51
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	40
Duloxetine	Serotonin and norepinephrine reuptake inhibitor	14
Endoxan		29
Epirubicin hydrochloride	Anthracycline topoisomerase inhibitor	31
Erbitux	Epidermal growth factor receptor antagonist	16
Etoposide	Topoisomerase inhibitor	76
Filgrastim	Leukocyte growth factor	12
Fludarabine	Nucleoside metabolic inhibitor	14
Fludarabine phosphate	Nucleoside metabolic inhibitor	13
Fluorouracil	Nucleoside metabolic inhibitor	64
Fulvestrant	Estrogen receptor antagonist	34
Furosemide	Loop diuretic	14
Gemcitabine	Nucleoside metabolic inhibitor	19
Herceptin	HER2/neu receptor antagonist	16
Hydrochlorothiazide	Thiazide diuretic	10
Ibrance	Kinase inhibitor	22
Ifosfamide	Alkylating drug	17
Irinotecan		13
Irinotecan hydrochloride	Topoisomerase inhibitor	11
Kisqali	Kinase inhibitor	21
Leponex		12
Letrozole	Aromatase inhibitor	28
Lithium carbonate	Mood stabilizer	10
Mabthera		23
Mesna	Cytoprotective agent	10
Methotrexate	Folate analog metabolic inhibitor	89
Methylprednisolone	Corticosteroid	13
Mycophenolate mofetil	Antimetabolite immunosuppressant	20
Olanzapine	Atypical antipsychotic	45
Oxaliplatin	Platinum-based drug	32
Paclitaxel	Microtubule inhibitor	72
Palbociclib	Kinase inhibitor	10
Panaldine		10
Pantoprazole	Proton pump inhibitor	11
Pegasys	Interferon alpha	24
Pembrolizumab	Programmed death Receptor-1 blocking antibody	18
Pemetrexed	Folate analog metabolic inhibitor	22
Perjeta	HER2/neu receptor antagonist	11
Pirarubicin Hydrochloride		33
Plavix	P2Y12 platelet inhibitor	18
Prednisolone	Corticosteroid	33
Prednisone	Corticosteroid	52
Propafenone	Antiarrhythmic	14
Quetiapine	Atypical antipsychotic	18
Revlimid	Thalidomide analog	16
Ribavirin	Nucleoside analog antiviral	18
Ribociclib	Kinase inhibitor	21
Risperdal	Atypical antipsychotic	16
Risperidone	Atypical antipsychotic	10
Rituximab	CD20-directed cytolytic antibody	108
Ruxolitinib	Janus kinase inhibitor	12
Seroquel	Atypical antipsychotic	28
Sodium chloride	Osmotic laxative	61
Tacrolimus	Calcineurin inhibitor immunosuppressant	10
Taxotere		10
Tislelizumab		13
Tocilizumab	Interleukin-6 receptor antagonist	11
Trastuzumab	HER2/neu receptor antagonist	15
Valproate sodium	Anti-epileptic agent	23
Vancomycin	Glycopeptide antibacterial	11
Venclexta	BCL-2 inhibitor	12
Venetoclax	BCL-2 inhibitor	61
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	11
Vincristine		58
Vincristine sulfate	Vinca alkaloid	25
Vindesine		14
Vinorelbine	Vinca alkaloid	15
Zyprexa	Atypical antipsychotic	28

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 50 pharmacologic classes with 10 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Granulocytopenia name, in order of name
Class	Reports with this term
Alkylating drug	252
Aminosalicylate	11
Anthracycline topoisomerase inhibitor	126
Anti-epileptic agent	81
Antiarrhythmic	14
Antimetabolite immunosuppressant	26
Aromatase inhibitor	33
Atypical antipsychotic	3,409
Azole antifungal	11
BCL-2 inhibitor	73
Calcineurin inhibitor immunosuppressant	31
CD20-directed cytolytic antibody	128
Cephalosporin antibacterial	27
Corticosteroid	145
Cytoprotective agent	19
Epidermal growth factor receptor antagonist	26
Estrogen receptor antagonist	34
Fluoroquinolone antibacterial	14
Folate analog	13
Folate analog metabolic inhibitor	117
Glycopeptide antibacterial	15
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	17
HER2/neu receptor antagonist	48
HMG-CoA reductase inhibitor	11
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	13
Interferon alpha	26
Interleukin-6 receptor antagonist	13
Janus kinase inhibitor	16
Kinase inhibitor	108
Leukocyte growth factor	24
Loop diuretic	21
Macrolide antimicrobial	13
Microtubule inhibitor	153
Mood stabilizer	22
Nonsteroidal anti-inflammatory drug	14
Nucleoside analog antiviral	21
Nucleoside metabolic inhibitor	279
Osmotic laxative	63
P2Y12 platelet inhibitor	18
Platinum-based drug	210
Programmed death Receptor-1 blocking antibody	26
Proton pump inhibitor	31
Purine antimetabolite	11
Serotonin and norepinephrine reuptake inhibitor	32
Thalidomide analog	24
Thiazide diuretic	10
Topoisomerase inhibitor	95
Tumor necrosis factor blocker	12
Vascular endothelial growth factor inhibitor	49
Vinca alkaloid	40

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Granulocytopenia, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Granulocytopenia
Age	Reports	Share
Under 2	42	0.7%
2 to 11	73	1.3%
12 to 17	169	3%
18 to 44	1,689	29.9%
45 to 64	1,821	32.3%
65 to 74	526	9.3%
75 and over	280	5%
Age not given	1,045	18.5%

Sex of the patient in the reports that record Granulocytopenia
Sex	Reports	Share
Female	2,430	43%
Male	2,903	51.4%
Unknown or not given	312	5.5%

Age and sex are as the report gives them. 62.9% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Granulocytopenia: adverse event reports that record this term. https://reportedreactions.com/reaction/granulocytopenia/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Granulocytopenia mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page